JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Recursion Pharmaceuticals Inc

Cerrado

SectorSalud

6.04 5.96

Resumen

Variación precio

24h

Actual

Mínimo

5.95

Máximo

6.14

Métricas clave

By Trading Economics

Ingresos

31M

-172M

Ventas

4.4M

19M

Margen de beneficio

-899.843

Empleados

800

EBITDA

44M

-148M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+3.84% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

356M

2.9B

Apertura anterior

0.08

Cierre anterior

6.04

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

353 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 oct 2025, 18:41 UTC

Ganancias

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 oct 2025, 18:31 UTC

Ganancias

Correction to Procter & Gamble to Focus on Innovation

24 oct 2025, 16:25 UTC

Principales Movimientos del Mercado

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 oct 2025, 21:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 oct 2025, 21:24 UTC

Charlas de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct 2025, 21:07 UTC

Ganancias

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct 2025, 20:58 UTC

Ganancias

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 20:40 UTC

Ganancias

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct 2025, 20:24 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:23 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:13 UTC

Ganancias

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 20:07 UTC

Charlas de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct 2025, 19:40 UTC

Charlas de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct 2025, 19:35 UTC

Charlas de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct 2025, 19:33 UTC

Ganancias

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 oct 2025, 19:29 UTC

Charlas de Mercado

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 oct 2025, 18:52 UTC

Ganancias

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct 2025, 18:41 UTC

Ganancias

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct 2025, 18:03 UTC

Ganancias

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 oct 2025, 18:02 UTC

Ganancias

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 oct 2025, 18:00 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 oct 2025, 16:57 UTC

Ganancias

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 oct 2025, 16:54 UTC

Charlas de Mercado

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 oct 2025, 16:44 UTC

Charlas de Mercado
Ganancias

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 oct 2025, 16:39 UTC

Charlas de Mercado
Ganancias

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 oct 2025, 16:33 UTC

Ganancias

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 16:23 UTC

Ganancias

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 16:07 UTC

Ganancias

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparación entre iguales

Cambio de precio

Recursion Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

3.84% repunte

Estimación a 12 meses

Media 5.95 USD  3.84%

Máximo 8 USD

Mínimo 3 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Recursion Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

1

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.15 / 4.75Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

353 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat